RATIO-SALBUTAMOL SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

SALBUTAMOL (SALBUTAMOL SULFATE)

Tilgjengelig fra:

TEVA CANADA LIMITED

ATC-kode:

R03AC02

INN (International Name):

SALBUTAMOL

Dosering :

0.5MG

Legemiddelform:

SOLUTION

Sammensetning:

SALBUTAMOL (SALBUTAMOL SULFATE) 0.5MG

Administreringsrute:

INHALATION

Enheter i pakken:

2.5ML

Resept typen:

Prescription

Terapeutisk område:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Produkt oppsummering:

Active ingredient group (AIG) number: 0108887009; AHFS:

Autorisasjon status:

CANCELLED POST MARKET

Autorisasjon dato:

2019-07-09

Preparatomtale

PRODUCT MONOGRAPH
RATIO-SALBUTAMOL
salbutamol sulphate nebules P.F. 1.25MG/2.5 ML, 5.0 MG/2.5 ML AMPOULES
Bronchodilator
(beta
2
-adrenergic stimulant)
TEVA CANADA LIMITED..
30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA, M1B 2K9
Control: 165512
DATE OF PREPARATION:
JULY 3, 2013
Teva Canada Limited.
2/32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS AND PRECAUTIONS
......................................................................................................................
3
ADVERSE REACTIONS
........................................................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................................................
7
DOSAGE AND ADMINISTRATION
....................................................................................................................
10
OVERDOSAGE
.....................................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
...................................................................................................
12
STORAGE AND STABILITY
...............................................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................